A SPAC III Acquisition Corp. filings document the regulatory record of a British Virgin Islands blank-check company with Nasdaq-listed units, Class A ordinary shares and rights. Its disclosures cover 8-K material events, proxy and governance matters, shareholder votes, capital-structure changes, sponsor share arrangements and SPAC security terms.
The filing record includes amendments to the company’s memorandum and articles of association, business-combination deadline-extension matters, unregistered equity issuance disclosure, PFIC annual statement materials and exhibits related to formal corporate actions.
ASPAC III Acquisition Corp. shareholders approved an amendment extending the deadline to complete an initial business combination from November 12, 2026 to November 12, 2028. The amended charter became effective October 20, 2026, and permits up to 48 months from the company’s initial public offering to complete a combination.
At the October 19, 2026 extraordinary general meeting, 2,146,309 ordinary shares were voted, representing 91.82% of the 2,337,581 ordinary shares outstanding and entitled to vote as of September 22, 2026. The proposal received 2,139,817 votes for, 6,491 against and one abstention. Holders tendered 8,093 ordinary shares for redemption in connection with the meeting.
ASPAC III Acquisition Corp. (ASPC) asks shareholders to extend its deadline for completing a business combination from November 12, 2026, to November 12, 2028, subject to shareholder approval and registration of the amended charter. No additional funds would be deposited into the trust account. The proposed Bioserica transaction is not being voted on at this meeting.
As of September 22, 2026, the trust held approximately $3.06 million and the estimated redemption price was approximately $10.82 per public share. Nasdaq notified the company that its stockholders’ equity for the quarter ended March 31, 2026, was below the $2.5 million continued-listing requirement, with until November 12, 2026, to regain compliance. The sponsor indicated it will vote for the extension; its 1,785,000 shares represented approximately 76.4% of outstanding shares on the record date. Nasdaq rules separately require a business combination within 36 months of the IPO.
A SPAC III Acquisition Corp. (ASPC) is asking shareholders to approve amendments to its charter to extend the deadline to complete a business combination from November 12, 2026 to November 12, 2028. This would lengthen the SPAC’s life from 24 to 48 months after its IPO to allow more time to close the previously announced Bioserica Business Combination.
Holders of Public Shares may redeem for cash a pro rata portion of the funds in the Trust Account in connection with this extension vote, regardless of how they vote or whether they vote, and will retain a separate redemption right at the later merger vote. The sponsor currently does not plan to add any funds to the Trust Account in connection with the extension.
The sponsor beneficially owns about 76.4% of outstanding ordinary shares and has indicated it will vote for the extension, which would assure approval. If the charter changes are not approved and no business combination is completed by November 12, 2026, ASPC would redeem 100% of Public Shares from the Trust Account and then liquidate, with founder shares and private placement units expiring worthless. ASPC also discloses that it is below Nasdaq’s $2.5 million minimum stockholders’ equity requirement and faces potential delisting if it does not regain compliance and complete a business combination within 36 months of its IPO.
A SPAC III Acquisition Corp. is a blank check company seeking an ESG and materials technology Business Combination and has not begun operating activities. As of June 30, 2026, it reported total assets of $3.83 million, including $3.03 million in a Trust Account and $633,724 in cash, with working capital of $237,744.
For the six months ended June 30, 2026, the company recorded a net loss of $129,206, compared with net income in the prior year period, mainly due to substantially lower interest income on the Trust Account. Following redemptions of 5,717,419 Class A shares for $59.50 million, only 282,581 public Class A shares remain redeemable and the sponsor holds approximately 76.4% of the 2,337,581 outstanding ordinary shares.
The company has until November 12, 2026 (the extended Combination Period) to complete its initial Business Combination, or it will liquidate the Trust Account. Management states that mandatory liquidation risk and the need for additional financing raise substantial doubt about its ability to continue as a going concern. A Nasdaq notice cited stockholders’ equity below $2.5 million; Nasdaq accepted a remediation plan and granted time to regain compliance by November 12, 2026, but there is no assurance of success. A pending all-stock merger with Bioserica International Limited values the target consideration at $217.86 million, subject to customary closing conditions.
A SPAC III Acquisition Corp. reported that Nasdaq has notified the company it no longer meets the exchange’s stockholders’ equity standard for listing. The Form 10-Q for the quarter ended March 31, 2026 showed equity below the $2,500,000 minimum required under Nasdaq Listing Rule 5550(b)(1).
The company has 45 calendar days from the May 20, 2026 notice to submit a plan to regain compliance, and Nasdaq may grant up to 180 calendar days from that date to demonstrate compliance if the plan is accepted. The company is preparing a compliance plan but states there is no assurance it will be able to regain compliance or that Nasdaq will accept its plan.
A SPAC III Acquisition Corp. reported a net loss of $113,988 for the quarter ended March 31, 2026, compared with net income of $413,202 a year earlier. The loss mainly reflects ongoing general, legal and professional expenses as interest income on the trust account declined sharply.
The Company held $670,328 of cash outside its trust and $3,006,138 of investments in its trust account, with 282,581 Class A shares classified as redeemable. After prior redemptions of 5,717,419 shares for $59,502,058, the Sponsor now owns about 76.4% of 2,337,581 outstanding shares. A pending business combination with Bioserica values that transaction at $217,860,000, and management discloses substantial doubt about the Company’s ability to continue as a going concern if no deal closes by November 12, 2026.
A SPAC III Acquisition Corp. reported that it has made its PFIC Annual Statement for fiscal year 2025 available to holders of its Class A ordinary shares. The company believes it may be treated as a passive foreign investment company for U.S. tax purposes for that year and is providing data to help U.S. shareholders consider a Qualified Electing Fund election. Because redemptions significantly changed shares outstanding during 2025, the company calculated per-share, per-day figures using a time-segmented approach. For January 1 to October 26, 2025, it shows ordinary earnings of 0 and no net capital gains; for October 27 to December 31, 2025, it reports ordinary earnings of 0.002124334 and no net capital gains. The statement notes that company redemptions are generally treated as dispositions for U.S. tax purposes and strongly encourages shareholders to consult their own tax advisors.
A SPAC III Acquisition Corp., a British Virgin Islands blank check company, filed its annual report describing progress toward completing a business combination and key structural changes. The company raised $60,000,000 in its IPO and related private placements, placing those proceeds in a trust account for future redemptions and a merger.
During 2025 it signed a Merger Agreement with Bioserica International Limited, a BVI holding company with operations primarily in China, valuing the acquisition at $217,860,000, payable in newly issued PubCo Class A and Class B ordinary shares. Shareholders approved extending the deadline to complete a business combination to November 12, 2026, and 5,717,419 Class A ordinary shares were redeemed in connection with that vote. As of December 31, 2025, $2,979,936 remained in the trust account and, as of March 4, 2026, 2,337,481 Class A and 100 Class B ordinary shares were outstanding.
The report emphasizes that the company has not begun operations and will not generate operating revenue until after an initial business combination. It describes extensive legal and regulatory risks tied to acquiring a China-based business, including PRC foreign investment, data security, cybersecurity review, VIE structures, and the Holding Foreign Companies Accountable Act, as well as potential CFIUS review if it acquires certain U.S. businesses.
Mizuho Financial Group, Inc. filed Amendment No. 3 to a Schedule 13G for A SPAC III Acquisition Corp., reporting beneficial ownership of 0 common shares, representing 0.0% of the class as of 12/31/2025.
The filing shows Mizuho has no sole or shared voting or dispositive power over A SPAC III common shares. Mizuho is identified as a parent holding company, and it states the securities were held in the ordinary course of business and not for the purpose of influencing control.
Bank of Montreal and affiliates have filed an amended Schedule 13G reporting that they no longer beneficially own any Class A ordinary shares of ASPAC III Acquisition Corp. The filing lists Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. as reporting persons.
Each entity reports beneficial ownership of 0 shares, with 0% of the class, and no sole or shared power to vote or dispose of any shares. The filing states ownership of 5 percent or less of the class and certifies the securities were held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.